Hearburn pyrosis
Conditions
Interventions
During the study period of 6 weeks, patients will receive 3 times daily 200 mg
of benescoTM or a placebo Patients will fill out symptom questionnaires at
baseline and every week for the total durati
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Age above 18 years. - Symptoms of heartburn and/or acid regurgitation at least 3 times a week - A total reflux symptom score >=8 (measured through the GerdQ questionnaire score).
Exclusion criteria
Exclusion criteria: - Use of any medication with an effect on gastrointestinal motility, secretion or sensitivity that cannot be stopped for the duration of the study except antacids (e.g. proton pump inhibitors, H2-blockers, antidepressants, prokinetics). Medication must be stopped at least two weeks upon inclusion. - Less than 50% response to PPI (if previously used) - Known Barrett*s esophagus - History of gastric or esophageal surgery - Known allergy to one of the ingredients of Benesco - Severe and clinically unstable concomitant disease (e.g. liver, cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders) - Pregnant, lactating or fertile women (without contraception)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is treatment success, defined as a reduction in symptoms of 50%. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes include reduction in symptom frequency and symptom severity (using a symptom diary). | — |
Countries
Netherlands
Outcome results
None listed